Insmed Q1 revenue up 23% to $65.2M; net loss widens to $159.8M; pipeline on track

INSMED Inc

2023-Q1 EPS reported -$1.17 revenue$65,214,000

ARIKAYCE global revenue $65.2M, up 23% YoY; U.S. net sales $49.1M, Japan $13.2M.
Net loss $159.8M ($1.17/share) vs $94.6M ($0.80) in Q1 2022; R&D spend rose to $127.9M.
Cash and securities $999M at March 31, 2023, down from $1.15B at Dec 31, 2022.
Phase 3 ASPEN enrollment completed (1,700+ patients); topline data expected Q2 2024.
Reaffirmed FY2023 ARIKAYCE revenue guidance $285M-$300M; appointed Makoto Nakamura GM Japan.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INSMED Inc reported the first quarter ended March 31, 2023 results: revenue $65.2 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2023
Revenue: $65.2 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue for the first quarter ended March 31, 2023, was $65.2 million, reflecting 23% year-over-year growth compared to total revenue of $53.1 million for the first quarter of 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

INSMED Inc filing history →

Source: SEC EDGAR

accession 0001140361-23-022852

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.